cn3
Monday, 6 November 2017
A Rare Bright Spot for Mylan
Little has gone right for Mylan recently, so the company and its investors can be forgiven for embracing a new drug as its next engine for growth.
from WSJ.com: Markets http://ift.tt/2hanDoE
via https://ifttt.com/ IFTTT
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment